Positive data from Syros SY-1425 and Azacitidine Phase 2 clinical trials for atrial for AML patients

Today, Syros Pharmaceuticals, inc.a(http:// a company dedicated to developing innovative therapies to control gene expression, announcedthat its selective osteolic acid receptor alpha (RARa) agonist SY-1425, in conjunction with the low-methylator azacitidine, obtainedpositive trial data for theof phase 2 clinical(http:// in the treatment of newly diagnosed patients with acute myeloid leukemia (AML)the trial's data also confirmed that RARA can be used as the best biomarker for predicting patients treated with SY-1425on SY-1425Syros's SY-1425 is a selective oral osteoid acid receptor alpha agonist called "first-in-class" that drives the expression of genes that promote cell differentiationpreclinical datashow that SY-1425 is combined with AML's standard therapy to have synergistic anti-tumor activityPreviously, SY-1425 was qualified for orphan drugby the u.SFDA(http://currently, SY-1425 is being treated in Phase 2 clinical trials for patients with primary treatment of AML and recurrent/difficult AML 　　In this ongoing Phase 2 clinical trial
, 40 AML patients who are not eligible for standard chemotherapy received a combination of SY-1425 and azacitidine The median age of these patients was 76 years, including 13 RARA-positive patients and 4 IRF8-positive patients As of August 22, 2019, 62% of patients with total remission and full remission and partial blood cell count remission (CRi) in the RARA-positive group and 54% of patients with full remission (including molecular remission and cytogenetic remission) were in the LARA-positive patient population The duration of remission (DOR) in patients reached a maximum of 344 days, and 82% of patients achieved or maintained a state of non-dependence on blood transfusions